Compare Charles River Laboratories Intl. Inc (CRL) vs Hut 8 Corp (HUT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Hut 8 Corp — how do they compare? Charles River Laboratories Intl. Inc trades at $302.17 (market cap $14.23B), while Hut 8 Corp trades at $84.27 (market cap $9.82B). The key difference: Charles River Laboratories Intl. Inc is the larger of the two by market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Hut 8 Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Hut 8 Corp for 11 Days on average.
| CRL | HUT | |
|---|---|---|
Market Cap | $14.23B | $9.82B |
Volume | 1,176,885 | 10,272,678 |
Sector | Health | Financials |
52-Week High | $310.77 | $133.02 |
52-Week Low | $149.93 | $33.76 |
Typical Hold Time | 33 Days | 11 Days |
Enterprise Value | $17.06B | $17.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
Hut 8 Corp. (HUT) trades at $81.20, down 9.07% amid a bearish technical signal. The company reported a net loss of $226.15 million in 2025 despite revenue of $235.12 million, with negative cash flow from operations. Recent news highlights a $1.07 billion credit facility and strong analyst buy ratings, with a consensus price target of $162.69 suggesting significant upside potential.
The outlook is mixed: robust analyst support and AI infrastructure growth opportunities contrast with persistent losses and high valuation ratios. Key risks include execution on profitability and sensitivity to sector sentiment. The stock's near-term direction hinges on earnings improvement and contract execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →
